National Consensus Conference on the Pharmacoeconomics of Treatment-Resistant Schizophrenia. Dallas, TX, USA, 1997/10/04.
Based upon the Illinois Department of Mental Health and Developmental Disabilities'computerized clinical information system, with its integration of client-specific clinical data, a 5-year retrospective study was designed to determine the clinical effectiveness and economic impact of the use of clozapine for treatment-resistant schizophrenia.
The study sample consisted of 518 hospitalized, treatment-resistant patients.
At the end of 5 years, 78% were well maintained on clozapine.
Two hundred forty-three patients had been discharged to the community, and 62 had been transferred for treatment of medical or surgical problems.
Clozapine treatment was discontinued in 115 patients (22%). The drug was well tolerated, with a very low incidence of agranulocytosis.
Cost savings resulting from the discharge of the 243 clozapine-treated patients amounts to approximately $20 million per year.
A disease management algorithm has been developed allowing physicians to begin clozapine treatment for patients not successfully treated with 2 prior antipsychotic agents.
Adherence to this protocol throughout the state's mental health system would result in even greater savings.
Mots-clés Pascal : Schizophrénie, Résistance traitement, Chimiothérapie, Clozapine, Neuroleptique, Atypique, Psychotrope, Efficacité traitement, Analyse coût, Economie santé, Illinois, Etats Unis, Amérique du Nord, Amérique, Homme, Psychose, Dibenzodiazépine
Mots-clés Pascal anglais : Schizophrenia, Negative therapeutic reaction, Chemotherapy, Clozapine, Neuroleptic, Atypical, Psychotropic, Treatment efficiency, Cost analysis, Health economy, Illinois, United States, North America, America, Human, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0185980
Code Inist : 002B02B03. Création : 16/11/1999.